Pages that link to "Q34897189"
Jump to navigation
Jump to search
The following pages link to Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study (Q34897189):
Displaying 50 items.
- Hepatitis B virus reactivation with rituximab-containing regimen (Q26830484) (← links)
- Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics (Q26998412) (← links)
- Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin’s lymphoma patients after rituximab chemotherapy (Q27489375) (← links)
- Exploring new territory: considering the future (Q28222277) (← links)
- The potential utility of B cell-directed biologic therapy in autoimmune diseases (Q33377109) (← links)
- Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks (Q33378620) (← links)
- Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development (Q33380175) (← links)
- Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients (Q33387348) (← links)
- Prevention of hepatitis B virus reactivation under rituximab therapy (Q33390799) (← links)
- Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. (Q33395260) (← links)
- The pathology of T cells in systemic lupus erythematosus (Q33598213) (← links)
- Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. (Q33735212) (← links)
- Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches (Q34170097) (← links)
- The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). (Q34373452) (← links)
- Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice (Q34909225) (← links)
- Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study (Q35092872) (← links)
- Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy (Q35418255) (← links)
- Understanding lupus nephritis: diagnosis, management, and treatment options (Q36008840) (← links)
- Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases (Q36076063) (← links)
- Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus (Q36168964) (← links)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 (Q36171750) (← links)
- Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis (Q36219954) (← links)
- Genetics of Lupus Nephritis: Clinical Implications. (Q36300008) (← links)
- Developments in lupus 2006 (Q36392336) (← links)
- Emerging drug therapies for systemic lupus erythematosus (Q36634248) (← links)
- Biological therapies: new treatment options for ANCA-associated vasculitis? (Q36764935) (← links)
- B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family (Q36897408) (← links)
- New treatment strategies for proliferative lupus nephritis: keep children in mind! (Q36915693) (← links)
- Adenosine production by human B cells and B cell-mediated suppression of activated T cells (Q36983750) (← links)
- Development of biologicals for the therapy of lupus erythematosus (Q37012093) (← links)
- Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date (Q37021227) (← links)
- Rituximab: beyond simple B cell depletion (Q37073637) (← links)
- Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome (Q37123206) (← links)
- Biomarkers and updates on pediatrics lupus nephritis (Q37167062) (← links)
- Update on the management of lupus nephritis: let the treatment fit the patient (Q37255744) (← links)
- Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis (Q37302417) (← links)
- B-cell-directed therapy for inflammatory skin diseases (Q37369906) (← links)
- Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion? (Q37477848) (← links)
- Rituximab in lupus and beyond: the state of the art. (Q37477857) (← links)
- B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? (Q37641025) (← links)
- The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant (Q37689179) (← links)
- Update on emerging drug therapies for systemic lupus erythematosus (Q37690745) (← links)
- Off-label use of rituximab in systemic lupus erythematosus: a systematic review (Q37692210) (← links)
- Effector and regulatory B cells: modulators of CD4+ T cell immunity (Q37708012) (← links)
- Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). (Q37709460) (← links)
- B-cell-targeted therapies in systemic lupus erythematosus (Q37729368) (← links)
- Rituximab therapy in lupus nephritis: current clinical evidence (Q37737138) (← links)
- Management of systemic lupus erythematosus in Chinese patients (Q37754815) (← links)
- Treatment of proliferative lupus nephritis: a slowly changing landscape (Q37822658) (← links)
- Update on the role of rituximab in kidney diseases and transplant (Q37970443) (← links)